PT - JOURNAL ARTICLE AU - Jorine E. Hartman AU - Lowie E.G.W. Vanfleteren AU - Eva M. van Rikxoort AU - Karin Klooster AU - Dirk-Jan Slebos TI - Endobronchial valves for severe emphysema AID - 10.1183/16000617.0121-2018 DP - 2019 Jun 30 TA - European Respiratory Review PG - 180121 VI - 28 IP - 152 4099 - http://err.ersjournals.com/content/28/152/180121.short 4100 - http://err.ersjournals.com/content/28/152/180121.full SO - EUROPEAN RESPIRATORY REVIEW2019 Jun 30; 28 AB - The results of the randomised controlled trials investigating the bronchoscopic lung volume reduction treatment using endobronchial valves (EBV) are promising, and have led to their inclusion in treatment guidelines, US Food and Drug Administration approval and inclusion in routine care in an increasing number of countries. The one-way valve treatment has advanced and is now a regular treatment option. However, this new phase will lead to new challenges in terms of implementation. We believe that key issues in future research concern advanced patient selection, improved methods for target lobe selection, increased knowledge on the predictive risk of a pneumothorax, positioning of pulmonary rehabilitation in conjunction with the EBV treatment, the positioning of lung volume reduction surgery versus EBV treatment, and the long-term efficacy, adverse events, impact on exacerbations and hospitalisations, costs and survival. Hopefully, the increasing number of patients treated, the setup of (inter)national registries and future research efforts will further optimise all aspects of this treatment.EBV treatment for severe emphysema patients improves clinical and patient reported outcomes and has become a guideline treatment, but also has future challenges. http://ow.ly/Jskd30o3ufm